Aventis/Novartis update
This article was originally published in The Tan Sheet
Executive Summary
No formal negotiations have taken place on price tag for France's number one pharmaceutical company, Aventis CEO Igor Landau says in an April 2 conference call. Landau said the firm has "close to two months" to accelerate price negotiations if Novartis maintains interest; Aventis will propose resolutions including a 2003 dividend to shareholders at a May 19 annual meeting. If the merger is successful, Novartis likely would spin off non-core pharmaceutical and consumer brands into a separate entity (1"The Tan Sheet" March 29, 2004, p. 5)...
You may also be interested in...
Novartis/Aventis Consumer Products Combo Would Be Divested
Novartis would spin-off a combination of its consumer health products and Aventis' older drugs if the two companies were to merge
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.